Reviva Price To Book Ratio from 2010 to 2025

RVPHW Stock  USD 0.27  0.11  68.75%   
Reviva Pharmaceuticals Price To Book Ratio yearly trend continues to be fairly stable with very little volatility. Price To Book Ratio is likely to outpace its year average in 2025. Price To Book Ratio is a ratio used to compare a firm's market value to its book value, calculated by dividing the current closing price of the stock by the latest quarter's book value per share. View All Fundamentals
 
Price To Book Ratio  
First Reported
2010-12-31
Previous Quarter
19.29
Current Value
20.25
Quarterly Volatility
9.76681758
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Reviva Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reviva Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 10 K, Net Interest Income of 602.5 K or Interest Income of 602.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 20.25. Reviva financial statements analysis is a perfect complement when working with Reviva Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Reviva Pharmaceuticals Correlation against competitors.

Latest Reviva Pharmaceuticals' Price To Book Ratio Growth Pattern

Below is the plot of the Price To Book Ratio of Reviva Pharmaceuticals Holdings over the last few years. It is a ratio used to compare a firm's market value to its book value, calculated by dividing the current closing price of the stock by the latest quarter's book value per share. Reviva Pharmaceuticals' Price To Book Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Reviva Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Price To Book Ratio10 Years Trend
Slightly volatile
   Price To Book Ratio   
       Timeline  

Reviva Price To Book Ratio Regression Statistics

Arithmetic Mean1.87
Geometric Mean5.47
Coefficient Of Variation523.62
Mean Deviation7.75
Median(4.30)
Standard Deviation9.77
Sample Variance95.39
Range25.7269
R-Value0.82
Mean Square Error34.30
R-Squared0.66
Significance0.0001
Slope1.67
Total Sum of Squares1,431

Reviva Price To Book Ratio History

2025 20.25
2024 19.29
2023 21.43
2022 6.73
2021 1.49
2020 3.6

About Reviva Pharmaceuticals Financial Statements

Reviva Pharmaceuticals investors use historical fundamental indicators, such as Reviva Pharmaceuticals' Price To Book Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Reviva Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price To Book Ratio 19.29  20.25 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Reviva Stock Analysis

When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.